Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative

Hendriks, Hans R, Govaerts, Anne-Sophie, Fichtner, Iduna, Burtles, Sally, Westwell, Andrew and Peters, Godefridus J 2017. Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. British Journal of Cancer 117 , pp. 195-202. 10.1038/bjc.2017.167

[thumbnail of Pharmacologically%20directed%20strategies%20in%20academic%20anticancer%20drug%20discovery%20based%20on%20the%20European%20NCI%20compounds%20initiative%20[1].pdf]
PDF - Accepted Post-Print Version
Download (533kB) | Preview


Background: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in vivo testing of potential anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell screen. Methods: Over a period of more than twenty years the EORTC—Cancer Research Campaign panel reviewed ~2000 compounds of which 95 were selected for further evaluation. Selected compounds were stepwise developed with clear go/no go decision points using a pharmacologically directed programme. Results: This approach eliminated quickly compounds with unsuitable pharmacological properties. A few compounds went into Phase I clinical evaluation. The lessons learned and many of the principles outlined in the paper can easily be applied to current and future drug discovery and development programmes. Conclusions: Changes in the review panel, restrictions regarding numbers and types of compounds tested in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation of the European NCI programme in 2017 and its transformation into an academic platform of excellence for anticancer drug discovery and development within the EORTC-PAMM group. This group remains open for advice and collaboration with interested parties in the field of cancer pharmacology.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Subjects: R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords: EORTC-PAMM; CRUK; in vitro screen; pharmacological approach; anticancer drug discovery and development; PDX; European NCI compounds; academic platform
Publisher: Cancer Research UK
ISSN: 0007-0920
Date of First Compliant Deposit: 27 June 2017
Date of Acceptance: 12 May 2017
Last Modified: 02 Aug 2018 14:27

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics